Kadmon Holdings Inc (NYSE:KDMN) shares saw unusually-strong trading volume on Friday . Approximately 10,916,000 shares traded hands during trading, an increase of 1,151% from the previous session’s volume of 872,445 shares.The stock last traded at $3.87 and had previously closed at $3.72.
A number of equities analysts have recently weighed in on KDMN shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kadmon in a research note on Friday, March 9th. Zacks Investment Research raised shares of Kadmon from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 10th. Finally, ValuEngine raised shares of Kadmon from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $11.55.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.03. The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $2.67 million. equities analysts forecast that Kadmon Holdings Inc will post -0.96 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its holdings in Kadmon by 66.6% in the 4th quarter. Bank of New York Mellon Corp now owns 59,430 shares of the company’s stock valued at $216,000 after purchasing an additional 23,763 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Kadmon in the 1st quarter valued at about $106,000. Wells Fargo & Company MN lifted its holdings in Kadmon by 38.5% in the 4th quarter. Wells Fargo & Company MN now owns 102,418 shares of the company’s stock valued at $370,000 after purchasing an additional 28,462 shares in the last quarter. Citadel Advisors LLC lifted its holdings in Kadmon by 181.3% in the 1st quarter. Citadel Advisors LLC now owns 49,500 shares of the company’s stock valued at $210,000 after purchasing an additional 31,906 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in Kadmon in the 1st quarter valued at about $139,000. Institutional investors and hedge funds own 64.07% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.